Clinical study to verify the effectiveness of two drugs to prevent inflammation of the Pancreas after performing the Endoscopic Retrograde Cholangiopancreatography procedure
Phase 3
Recruiting
- Conditions
- PancreatitisK85.8
- Registration Number
- RBR-10nnzgqh
- Lead Sponsor
- Faculdade de Medicina de Sao Jose do Rio Preto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients submitted to Endoscopic Retrograde Cholangiopancreatography; of both sexes; aged over 18 years
Exclusion Criteria
Patients under 18 years of age; pregnant women; nursing mothers; those who do not accept or are not able to perform the Endoscopic Retrograde Cholangiopancreatography Exam(s) and follow-up during the study; Patients who lost clinical and laboratory follow-up due to hospital transfer or early death from severe cholangitis; patients with Non-steroidal anti-inflammatory drugs (NSAID) allergy and contraindication for use (i.e., active peptic ulcer, serum creatinine >1.4mg/dL, and single kidney) will also be excluded
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected to identify which non-steroidal anti-inflammatory drug (NSAID) used in this study is more effective in preventing the development of acute pancreatitis after endoscopic retrograde cholangiopancreatography. For this, a randomized, double-blind study model will be used and the NSAIDs used will be Diclofenac and Indomethacin
- Secondary Outcome Measures
Name Time Method o secondary outcomes expected